SEC Form 4 · accession 0001209191-17-040557
Spring Bank Pharmaceuticals, Inc. · SBPH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Arkowitz
Director
Period of report
Jun 15, 2017
Accepted (ET)
Jun 16, 2017 · 4:46 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001566373
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $14.27 | Jun 15, 2017 | A | 5,500 | A | — | Jun 14, 2027 | Common Stock | 5,500 | 5,500 | D |
Explanation of responses
- F1Pursuant to the Issuer's Non-Employee Director Compensation Policy, this option was automatically granted on June 15, 2017, the date of the Issuer's 2017 Annual Meeting of Stockholders, with shares subject to the option vesting in equal monthly installments until the first anniversary of the grant date.